uniQure N.V. (QURE) Posts New AMT-130 Data Showing Slower HD Progression
uniQure reported Phase I/II data for AMT-130 in Huntington’s disease: at 36 months in 15 high-dose patients, cUHDRS showed 80% slowing (nominal p=0.005) and TFC 67% (nominal p=0.011) vs external controls; at 48 months in 12 high-dose patients, TFC showed 61% slowing (nominal p=0.008).Material Detai…